Fire at serum institute, will this impact vaccine rollout?

  • January 25, 2021 02:18 PM AEDT
  • Hina Chowdhary
    Director, Equities Research Hina Chowdhary
    1706 Posts

    Hina Chowdhary is the Director, Equity Research at Kalkine and has an extensive experience of about 15 years in the area of Research, which includes 5+ years in Equities Research particularly.She has earned a Master of Science degree from the renowne...

Fire at serum institute, will this impact vaccine rollout?

Summary

  • Serum Institute of India's under-construction facility in Pune caught fire killing at least five workers.
  • The company confirmed Covishield vaccine production would not be impacted by the fire accident.
  • The international consignments schedules remain undisturbed.
Gold MTF non-AMP

On 21 January 2021, at least five construction workers lost their lives in a massive fire at the world's biggest vaccine manufacturer’s site in Western India. The Serum Institute of India's (SII) plant in Pune region caught fire. 

The SEZ3 building is located in the Special Economic Zone at Manjri, where vaccine production was planned after one month. The fire affected 4th and 5th floor of the building the most, whereas BCG vaccine lab is on the 3rd floor of the building which was relatively unaffected.

Image source: pixabay

The video recordings from the under-construction building were showing thick blaze. The unfortunate incident has also reportedly damaged much equipment at the site. The fire brigade personnel recovered all deceased body from the 5th floor of the building. Though the specific cause is still unknown, Rajesh Tope, Maharashtra Health Minister, said the cause of the fire was some welding work at the construction site.

How will the incident impact Covishield vaccine production?

Cyrus S Poonawalla, SII's Chairman and Managing Director, confirmed that the incident would not impact the production of Covishield, Oxford-AstraZeneca vaccine. The company has multiple production buildings to deal with such contingencies.

Oxford-AstraZeneca vaccine aka as Covishield is one of the two vaccines recommended by the Indian government for the vaccination program. Many developing countries depend on this vaccine from SII.

About Serum Institute of India 

India's No. 1 biotechnology company, Serum Institute of India Pvt. Ltd. manufactures and sells the highest number of vaccinations worldwide. It supplies over 1.5 billion vaccine doses for Polio, Tetanus, Pertussis, Diphtheria, r-Hepatitis B, Measles, Hib, BCG, Rubella, and Mumps. Dr Cyrus Poonawalla founded the company in the year 1966. 

Source: Megapixl

The facilities are equipped with high-tech machinery and most modern laboratories to manufacture and test the life-saving biologicals.

Do check: COVID 19 Vaccine Game Who will Pull Off?

SII dispatched international consignments post the incident

The scheduled consignments for the Covishield vaccine were dispatched after Thursday's fire accident. The flight carrying 1.5 million doses of Covishield vaccine for Myanmar was scheduled for same day the fire incidence took place. In contract, for Mauritius and Seychelles, the flight took off in the first half of 22 January 2021.

As part of the India’s vaccine donation program, Seychelles will be receiving 50k doses of Covishield vaccine. Moreover, Mauritius' consignment includes 100,000 doses of Covid-19 vaccine.

Good read: WHO Chief cautions over inequality amid global COVID-19 vaccine rollout

 


Disclaimer
The website https://kalkinemedia.com/au is a service of Kalkine Media Pty. Ltd. (Kalkine Media) A.C.N. 629 651 672. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.

 

   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK